gout: A condition characterized by painful swelling of the joints, which is caused by deposition of urate crystals.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
116 |
4. Check minimum number of eventsNone |
116 |
5. Include endpointsNone |
116 |
6. Filter based on genotype QC (FinnGen only) |
115 |
Control definitions (FinnGen only)
- Control exclude
- GOUT
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M10
- Name in latin
- Alia arthritis urica secundaria
Other secondary gout
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 964 | 358 | 599 |
| Only index persons | 824 | 302 | 522 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 71.27 | 76.27 | 68.30 |
| Only index persons | 70.71 | 75.58 | 67.90 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 115 | 36 | 79 |
| Unadjusted period prevalence (%) | 0.03 | 0.01 | 0.04 |
| Median age at first event (years) | 68.10 | 68.09 | 68.10 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 116
- Matched controls
- 1160
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M10.4
ICD-10 Finland
Other secondary gout
+∞
167.4
116
*
M10.9
ICD-10 Finland
Gout, unspecified
50.5
83.1
53
19
M04AA01
ATC
allopurinol; systemic
24.6
71.2
80
96
M10.0
ICD-10 Finland
Idiopathic gout
61.6
30.8
35
8
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
12.6
29.8
34
37
C03CA01
ATC
furosemide; systemic
6.7
21.6
83
316
B01AA03
ATC
warfarin; systemic
5.8
19.9
60
182
I50.0
ICD-10 Finland
Congestive heart failure
6.9
19.4
38
77
A46
ICD-10 Finland
Erysipelas
6.4
19.2
42
95
M10
ICD-10 Finland
Gout
19.3
17.2
26
17
212
Kela drug reimbursment
Gout
+∞
17.1
16
*
I50.9
ICD-10 Finland
Heart failure, unspecified
5.2
17.0
53
162
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
28.0
14.3
19
8
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.4
14.1
58
215
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.5
13.5
46
147
C03DA01
ATC
spironolactone; oral
5.0
13.4
37
100
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
32.8
13.4
17
6
I48
ICD-10 Finland
Atrial fibrillation and flutter
4.2
13.2
58
223
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.7
12.7
38
109
N18.8
ICD-10 Finland
Other chronic renal failure
18.6
12.7
19
12
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
6.1
12.6
25
50
H02AB06
ATC
prednisolone; systemic
4.3
12.3
82
416
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
4.6
12.2
37
107
I50.1
ICD-10 Finland
Left ventricular failure
6.6
12.2
22
40
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
5.2
11.9
29
70
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
5.4
11.7
27
62
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
4.2
11.6
41
133
A11CC03
ATC
alfacalcidol; systemic
19.6
11.6
17
10
A10BH05
ATC
linagliptin; oral
6.2
11.6
22
42
K78
ICPC
Atrial fibrillation/flutter
5.5
11.3
25
55
ZXD05
NOMESCO Finland
Urgent procedure
3.7
11.0
56
233
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
4.8
10.9
29
75
205
Kela drug reimbursment
Chronic hypertension
3.7
10.9
58
248
WX002
NOMESCO Finland
Sedation and analgesia
3.9
10.4
41
143
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
6.0
10.3
20
39
N02AA05
ATC
oxycodone; systemic
3.7
10.2
44
163
L04AA06
ATC
mycophenolic acid; systemic
60.2
9.8
11
*
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
3.9
9.8
36
119
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.5
9.6
78
425
SPAT1229
SPAT
Assessment of need for aid
5.5
9.5
20
42
C09AA02
ATC
enalapril; systemic
3.5
9.3
44
171
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
3.3
9.3
56
254
C01DA14
ATC
isosorbide mononitrate; oral
3.6
9.2
40
147
R50.9
ICD-10 Finland
Fever, unspecified
3.9
9.1
33
107
R06.0
ICD-10 Finland
Dyspnoea
3.3
9.1
52
227
B03XA02
ATC
darbepoetin alfa; parenteral
15.7
9.0
14
10
C07AB07
ATC
bisoprolol; oral
3.5
8.8
83
486
N19
ICD-10 Finland
Unspecified kidney failure
9.0
8.8
18
23
M01AB01
ATC
indometacin; systemic, rectal
4.6
8.6
23
59
TPH04
NOMESCO Finland
Cathetrisation of vein
3.4
8.5
40
154
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.8
8.4
31
102
XFP20
NOMESCO Finland
Check up of cardiac pacemaker
4.9
8.3
20
47
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.0
8.3
27
81
A10AE04
ATC
insulin glargine; parenteral
4.2
8.2
25
71
M13.9
ICD-10 Finland
Arthritis, unspecified
5.3
8.2
18
39
J01MA12
ATC
levofloxacin; systemic
3.4
8.2
39
151
N08.39*E11.2
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
24.1
8.2
11
5
A12AA04
ATC
calcium carbonate; oral
24.1
8.2
11
5
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
3.2
8.2
48
211
207
Kela drug reimbursment
Chronic arrhythmias
3.4
8.0
36
134
A28
ICPC
Limited function/disability NOS
3.4
8.0
38
147
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.3
7.9
41
167
D64.9
ICD-10 Finland
Anaemia, unspecified
3.8
7.9
28
89
N02AX02
ATC
tramadol; systemic, rectal
3.0
7.8
68
371
AA1AD
NOMESCO Finland
CT of head and brain
3.1
7.8
49
223
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
4.9
7.5
18
42
J01FF01
ATC
clindamycin; systemic
3.1
7.5
45
199
Z95.0
ICD-10 Finland
Presence of electronic cardiac devices
5.1
7.5
17
38
Z94.0
ICD-10 Finland
Kidney transplant status
+∞
7.4
7
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.3
7.3
21
57
V03AE01
ATC
polystyrene sulfonate; oral
21.7
7.3
10
5
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
3.7
7.3
26
83
AN1
HP
Coronary angiography
3.7
7.2
27
89
B01AF02
ATC
apixaban; oral
3.6
7.1
27
90
A10AB05
ATC
insulin aspart; parenteral
4.3
7.0
20
54
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
2.9
7.0
46
213
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.9
7.0
45
206
215
Kela drug reimbursment
Diabetes, non-insulin-treated
3.0
6.9
42
186
N03AX12
ATC
[U] gabapentin; oral
3.3
6.9
31
115
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
42.6
6.8
8
*
J01DB01
ATC
cefalexin; oral
4.6
6.8
104
757
Z49.0
ICD-10 Finland
Preparatory care for dialysis
24.2
6.8
9
*
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
24.2
6.8
9
*
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.7
6.7
24
76
XF400
NOMESCO Finland
ECG with 12 standard connections
3.1
6.6
34
136
I25.1
ICD-10 Finland
Atherosclerotic heart disease
2.8
6.6
47
226
A06AD11
ATC
lactulose; oral
3.3
6.6
30
112
137
Kela drug reimbursment
Uraemia requiring dialysis
73.7
6.5
7
*
B05DA
ATC
Isotonic solutions
73.7
6.5
7
*
127
Kela drug reimbursment
Transplant complication
73.7
6.5
7
*
I12.0
ICD-10 Finland
Hypertensive renal disease with renal failure
73.7
6.5
7
*
AN2
HP
Balloon angioplasty, including several vessels
10.1
6.5
12
13
R10.1
ICD-10 Finland
Pain localized to upper abdomen
3.2
6.5
30
113
JN3AD
NOMESCO Finland
Abdominal CT examination
3.8
6.4
22
68
103
Kela drug reimbursment
Diabetes, insulin-treated
2.8
6.4
47
229
N03.9
ICD-10 Finland
Chronic nephritic syndrome, unspecified
+∞
6.3
6
*
M10.3
ICD-10 Finland
Gout due to impairment of renal function
+∞
6.3
6
*
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.7
6.3
50
253
Z2221
NOMESCO Finland
Medical doctor
2.8
6.2
42
195
I50
ICD-10 Finland
Heart failure
8.0
6.1
13
18
E11.2
ICD-10 Finland
Type 2 diabetes mellitus, with renal complications
6.5
6.1
15
26
T90
ICPC
Diabetes non-insulin dependent
2.8
6.0
40
184
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
77
225
8.20
28.57
5.9
2.9
448.27
8169.22
umol/l
1.25
70
185
52
133
6.27
21.06
4.7
2.2
21.43
23.01
%
0.32
46
122
52
140
5.92
19.74
4.6
2.2
2.09
2.23
g/l
1.03
52
127
53
148
5.75
19.24
4.7
2.2
11.43
13.28
umol/l
1.00
53
137
50
151
5.06
16.16
3.5
3.0
0.80
0.81
mmol/l
0.17
44
141
48
160
4.41
13.32
2.5
2.0
—
—
—
0
0
86
450
4.52
12.40
15.4
6.4
1.20
1.21
mmol/l
0.16
77
379
80
411
4.05
11.52
11.9
6.0
1.21
1.21
mmol/l
0.09
73
369
33
92
4.62
11.36
7.8
4.5
2.41
2.30
mmol/l
0.03
28
70
27
65
5.11
11.07
2.1
1.4
—
—
—
0
0
84
466
3.91
10.35
41.6
14.0
1.56
1.34
inr
0.99
30
129
87
521
3.68
8.94
12.6
10.1
4.71
4.45
e9/l
0.43
77
451
17
20
9.75
8.66
1.6
1.5
—
—
—
0
0
71
382
3.21
8.61
2.7
1.9
87.18
92.01
pmol/l
0.31
47
198
68
357
3.19
8.61
6.3
3.2
—
—
—
0
0
24
64
4.47
8.59
2.6
1.8
—
—
—
0
0
48
217
3.07
7.72
3.4
2.4
—
—
—
0
0
31
110
3.48
7.40
2.5
1.8
—
—
—
0
0
55
276
2.89
7.23
7.0
3.8
23.04
10.62
mg/mmol
0.89
43
174
11
8
15.01
7.05
4.1
6.4
14.56
11.83
mg/l
—
11
8
15
21
8.03
6.96
1.4
1.3
—
—
—
0
0
29
111
3.15
6.05
2.6
2.0
—
—
—
0
0
15
27
6.21
5.92
1.6
1.1
—
—
—
0
0
30
120
3.02
5.79
6.0
6.4
11.79
11.71
kpa
0.03
30
114
30
120
3.02
5.79
6.0
6.4
4.88
5.06
kpa
0.49
30
114
16
42
4.26
5.76
3.9
1.5
—
—
—
0
0
68
416
2.53
5.62
4.6
2.5
—
—
—
0
0
16
35
5.13
5.43
2.3
1.9
—
—
—
0
0
12
20
6.56
5.06
1.2
1.4
—
—
—
0
0
12
20
6.56
5.06
1.2
1.4
—
—
—
0
0
16
38
4.71
5.06
2.9
2.2
—
—
—
0
0
28
119
2.78
4.79
1.3
1.3
4.82
9.52
u/ml
—
6
45
17
54
3.52
4.70
3.2
3.2
0.64
0.12
e6/l
0.87
17
54
40
209
2.39
4.47
2.4
1.6
1.40
1.74
mg/l
0.37
34
162
12
25
5.23
4.32
2.5
1.3
—
—
—
0
0
33
160
2.48
4.32
5.7
3.0
0.80
1.62
e6/l
0.59
18
91
11
21
5.67
4.26
1.5
1.1
—
—
—
0
0
32
155
2.47
4.18
4.0
1.8
31.63
29.59
s
0.59
32
149
29
134
2.55
4.18
1.4
1.3
22.07
36.05
iu/ml
—
7
41
10
18
5.97
4.07
2.4
1.3
—
—
—
0
0
33
168
2.35
3.84
4.8
2.8
1.40
0.88
e6/l
0.28
18
98
19
74
2.87
3.78
1.7
1.9
1.87
1.77
%
0.10
19
62
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
35
4.05
3.73
3.5
2.0
0.28
0.29
u/ml
—
7
17
17
63
2.99
3.68
4.4
6.5
23.40
24.67
mmol/l
0.69
17
63
18
73
2.73
3.32
7.2
3.8
41.89
61.36
ml/min/173m2
—
9
36
11
30
3.94
3.18
5.2
1.5
0.00
0.00
g/l
-0.00
11
30
10
26
4.11
3.06
1.6
1.5
—
—
—
0
0
16
64
2.74
3.02
1.4
1.5
—
—
—
0
0
7
13
5.65
2.91
1.3
1.2
—
—
—
0
0
103
871
2.63
2.86
48.5
16.0
23.75
25.99
mg/l
0.45
98
713
20
93
2.39
2.81
3.6
4.0
—
—
—
0
0
5
6
8.63
2.77
1.8
1.3
—
—
—
0
0
5
6
8.63
2.77
2.0
2.5
—
—
—
0
0
5
6
8.63
2.77
2.0
2.5
—
—
—
0
0
10
29
3.67
2.76
1.1
1.0
—
—
—
0
0
8
21
4.01
2.51
1.3
1.7
0.25
0.22
g/l
—
8
21
8
21
4.01
2.51
1.3
1.8
1.21
1.11
g/l
—
8
21
64
475
1.77
2.37
3.7
2.5
—
—
—
0
0
11
40
2.93
2.35
2.9
2.0
2.55
7.39
ug/l
0.30
11
35
8
23
3.66
2.31
1.9
1.7
—
—
—
0
0
8
23
3.66
2.31
1.9
1.7
—
—
—
0
0
6
13
4.80
2.30
1.5
1.5
—
—
—
0
0
7
18
4.07
2.29
1.6
1.4
—
—
—
0
0
7
19
3.85
2.18
1.4
2.3
—
—
—
0
0
55
400
1.71
2.12
8.5
4.4
42.09
52.26
ng/l
0.35
43
300
16
77
2.25
2.08
2.3
2.2
358.50
379.13
nmol/l
0.10
16
68
92
779
1.87
2.00
4.7
4.3
2.06
1.98
mu/l
0.23
85
677
16
80
2.16
1.91
1.9
2.0
0.21
0.22
g/l
0.04
16
71
6
17
3.66
1.86
1.2
2.2
—
—
—
0
0
5
12
4.30
1.84
1.6
1.5
—
—
—
0
0
60
462
1.62
1.77
5.1
4.0
0.00
0.00
estimate
—
10
83
59
454
1.61
1.73
6.8
5.4
0.00
0.00
estimate
—
10
91
5
13
3.97
1.73
1.6
1.5
—
—
—
0
0
5
13
3.97
1.73
1.6
1.1
—
—
—
0
0
5
13
3.97
1.73
1.6
1.5
—
—
—
0
0
5
14
3.68
1.63
1.6
1.4
—
—
—
0
0
5
14
3.68
1.63
1.6
1.4
—
—
—
0
0
8
32
2.61
1.63
7.5
2.9
47.85
45.26
mg/l
—
8
25
8
32
2.61
1.63
7.6
2.9
22.81
35.61
mg/l
—
8
25
5
15
3.43
1.54
2.0
2.1
—
—
—
0
0
5
15
3.43
1.54
2.0
2.1
—
—
—
0
0
5
15
3.43
1.54
2.0
2.1
—
—
—
0
0
6
21
2.95
1.52
1.3
2.0
—
—
—
0
0
9
37
2.55
1.52
2.6
2.5
—
—
—
0
0
95
839
1.73
1.46
42.6
15.2
60.79
76.75
ml/min/173m2
6.39
89
692
73
611
1.53
1.36
3.8
3.7
14.71
14.95
pmol/l
0.32
68
535
19
291
0.58
1.31
2.6
3.3
0.79
0.77
ug/l
0.04
14
205
5
18
2.85
1.30
1.4
2.1
—
—
—
0
0
7
30
2.42
1.14
1.9
1.9
—
—
—
0
0
7
31
2.34
1.12
1.9
1.8
—
—
—
0
0
56
457
1.44
1.11
5.2
4.0
0.00
0.00
estimate
—
9
98
9
45
2.08
1.08
1.3
1.9
—
—
—
0
0
7
33
2.19
1.07
1.9
1.2
—
—
—
0
0
94
849
1.57
1.07
6.4
4.8
6.41
6.10
mmol/l
1.10
88
757
29
377
0.69
0.92
3.6
4.6
24.50
20.68
%
—
8
193
100
926
1.58
0.90
57.5
18.7
133.47
82.99
umol/l
5.86
100
926
103
963
1.62
0.85
63.8
23.1
37.62
40.04
%
2.67
96
906
5
24
2.13
0.75
1.2
1.2
—
—
—
0
0
5
24
2.13
0.75
1.2
1.2
—
—
—
0
0
5
28
1.82
0.67
1.2
3.4
—
—
—
0
0
6
36
1.70
0.57
1.2
1.3
—
—
—
0
0
8
55
1.49
0.44
1.4
2.0
—
—
—
0
0
44
486
0.85
0.33
4.1
5.4
1.46
3.16
ug/l
1.31
39
424
32
357
0.86
0.26
6.1
4.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
9
113
0.78
0.21
7.8
8.6
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
175.83
—
0
13
0
13
0.00
0.21
0.0
1.6
—
3.14
—
0
7
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
8
72
1.12
0.16
1.5
1.4
—
—
—
0
0
27
249
1.11
0.13
4.8
4.2
0.00
0.00
estimate
—
8
86
23
212
1.11
0.11
2.0
1.6
1.67
1.34
mmol/l
1.02
23
167
9
100
0.89
0.06
1.8
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint GOUT_SCND and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| GOUT_SCND | 2.432 [1.7, 3.49] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.198 |
During the follow-up period (1.1.1998 — 31.12.2019), 157 out of 306 females with GOUT_SCND died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| GOUT_SCND | 3.031 [2.18, 4.21] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 239 out of 515 males with GOUT_SCND died.
Mortality risk
Mortality risk for people of age
years, who have GOUT_SCND.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.272% | 0.647% |
| 5 | 1.404% | 3.526% |
| 10 | 3.392% | 7.938% |
| 15 | 6.578% | 14.883% |
| 20 | 11.242% | 24.572% |
Relationships between endpoints
↥Index endpoint: GOUT_SCND – Other secondary gout
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data